Market revenue in 2023 | USD 144.4 million |
Market revenue in 2030 | USD 332.9 million |
Growth rate | 12.7% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.04% in 2023. Horizon Databook has segmented the Japan head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most advanced countries in this region, and its market is expected to grow at a rapid rate, owing to high government spending to curb cancer prevalence. The increase in cancer prevalence can be attributed to rapid growth in the geriatric population; Japan has a median age of 44 years, one of the highest in the world.
Japan, in contrast to other Asia Pacific countries, offers country-wide cancer screening programs for early disease detection, including for head and neck cancer. This program offers cancer screening to over 94% of the population in the country.
The confirmed diagnosis at an early stage leads to high treatment rates for the disease. The increase in number of anticancer drug approvals in Japan is expected to boost market growth. For instance, in November 2023, Alpha Tau Medical Ltd. announced submitting a premarket approval application for Alpha DaRT to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
Horizon Databook provides a detailed overview of country-level data and insights on the Japan head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Japan head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account